论文部分内容阅读
刻甫定(Capoten,captopril,巯甲丙脯胺酸)是近年来治疗高血压的口服新药。其降压机理主要是通过对肾素—血管紧张素—醛固酮系统的抑制而引起的。刻甫定选择性地抑制血管紧张素转化酶而阻滞血管紧张素Ⅰ(A Ⅰ)转变成血管紧张素Ⅱ(A Ⅱ),其结果可降低周围动脉的总阻力,从而使血压下降。1977年口服刻甫定开始试用于临床,八十年代初期,国外一些研究单位才开始系统应用,初步看来,它是一种强有力的降压药物,本文报导我们临床应用21例的疗效,供同志们参考。
Capoten (captopril, captopril) is an oral new drug for the treatment of hypertension in recent years. Its antihypertensive mechanism is mainly caused by the inhibition of the renin-angiotensin-aldosterone system. Carvedilon selectively inhibits angiotensin converting enzyme and blocks the conversion of angiotensin I (A ¢ ñ) to angiotensin ¢ ò (A ¢ ò). As a result, it decreases the total resistance of the peripheral arteries, resulting in a decrease in blood pressure. In 1977, oral administration of carvedilol began to be used in clinical trials. In the early 1980s, some foreign research institutes started systematic application. At first glance, it is a powerful antihypertensive drug. This article reports the clinical efficacy of 21 cases in our hospital, For comrades reference.